Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 1,030 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $13.66, for a total transaction of $14,069.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) traded up 0.74% during midday trading on Wednesday, hitting $13.65. 306,835 shares of the stock traded hands. The firm’s market cap is $941.26 million. Momenta Pharmaceuticals Inc. has a 12-month low of $7.86 and a 12-month high of $18.26. The company’s 50-day moving average is $12.20 and its 200 day moving average is $11.63.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The business earned $299.14 million during the quarter, compared to analyst estimates of $25.68 million. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. The company’s revenue for the quarter was up 2067.7% compared to the same quarter last year. On average, analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.15) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Several large investors have recently made changes to their positions in the stock. Cornerstone Capital Management Holdings LLC. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $135,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $818,000. Patten Group Inc. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $148,000. Virtus ETF Advisers LLC raised its stake in shares of Momenta Pharmaceuticals by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 55,093 shares of the biotechnology company’s stock worth $644,000 after buying an additional 6,942 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $525,000. 81.62% of the stock is owned by hedge funds and other institutional investors.

MNTA has been the subject of several analyst reports. JPMorgan Chase & Co. restated a “buy” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Barclays PLC restated a “buy” rating and issued a $19.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Aegis initiated coverage on shares of Momenta Pharmaceuticals in a report on Tuesday. They issued a “hold” rating and a $15.00 target price for the company. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a report on Friday, November 11th. Finally, Brean Capital set a $19.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. Momenta Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $16.10.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Momenta Pharmaceuticals Inc. (MNTA) SVP Sells 1,030 Shares of Stock” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of United States and international copyright & trademark law. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/23/insider-selling-momenta-pharmaceuticals-inc-mnta-svp-sells-1030-shares-of-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.